Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8736996 | 0.88 | TRPA1 (0.38) | TRPA1 | |
| SCHEMBL20738481 | 0.81 | ABCB11 (0.36) | TRPA1CXCR2 | |
| SCHEMBL25853270 | 0.81 | ABCB11 (0.36) | TRPA1CXCR2 | |
| SCHEMBL17132542 | 0.77 | PPARG (0.32) | TRPA1 | |
| SCHEMBL12169534 | 0.77 | ADRB2 (0.34) | TRPA1 | |
| SCHEMBL18793784 | 0.76 | GNRHR (0.33) | — | |
| SCHEMBL16955379 | 0.76 | ACHE (0.30) | — | |
| SCHEMBL8737000 | 0.75 | TRPV3 (0.39) | TRPA1 | |
| Hydrochloric Acid SCHEMBL18765899 | 0.74 | GNRHR (0.32) | — | |
| Hydrochloric Acid SCHEMBL29676868 | 0.74 | GNRHR (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759337-B2 | Gamma secretase modulators | MERCK SHARP & DOHME CORP. (US) | 2014-06-24 | — | — | US | disclosed |
| US-8518975-B2 | Gamma secretase modulators | Merck Sharp + Dohme Corp. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8450343-B2 | Gamma secretase modulators | SCHERING CORPORATION | 2013-05-28 | — | — | US | disclosed |
| US-20120245158-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2012-09-27 | — | — | US | disclosed |
| US-20120238546-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2012-09-20 | — | — | US | disclosed |
| US-20120232108-A1 | GAMMA SECRETASE MODULATORS | Merck, Sharp & Dohme, Corp. | 2012-09-13 | — | — | US | disclosed |
| US-20120135980-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2012-05-31 | — | — | US | disclosed |
| US-20120129846-A1 | GAMMA SECRETASE MODULATORS | Merck, Sharp & Dohme, Corp. | 2012-05-24 | — | — | US | disclosed |
| US-20110294784-A1 | GAMMA SECRETASE MODULATORS | MERCK SHARP & DOHME LLC | 2011-12-01 | — | — | US | disclosed |
| US-20110082153-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2011-04-07 | — | — | US | disclosed |
| US-20110027264-A1 | GAMMA SECRETASE MODULATORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | SCHERING CORPORATION | 2011-02-03 | — | — | US | disclosed |
| US-20110015190-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2011-01-20 | — | — | US | disclosed |
| US-20100298381-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232108-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | TRPA1 4697/4885CXCR2 4420/4885 |
| US-20110294784-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, GSAP | TRPA1 4440/4885CXCR2 4374/4885 |
| US-20120245158-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | TRPA1 4697/4885CXCR2 4420/4885 |
| US-20110082153-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | TRPA1 4671/4885CXCR2 4283/4885 |
| US-20120135980-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, GSAP | TRPA1 4440/4885CXCR2 4374/4885 |
| US-20120129846-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | TRPA1 4391/4885CXCR2 4211/4885 |
| US-20110027264-A1 | GAMMA SECRETASE MODULATORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | BACE1, BACE2, PSEN1 | TRPA1 4716/4885CXCR2 4532/4885 |
| US-20120238546-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | TRPA1 4682/4885CXCR2 4301/4885 |
| US-20100298381-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSENEN | TRPA1 4488/4885CXCR2 3980/4885 |
| US-20110015190-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | TRPA1 4712/4885CXCR2 3952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.